Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

LeoPatrizi/E+ via Getty Images Apogee Therapeutics: Analyzing the Recent Decline Amidst Innovations Apogee Therapeutics, Inc. (NASDAQ:APGE) stock has taken a breather since my last check in March. APG777, their Phase 1 SQ monoclonal antibody targeting IL13, was the primary focus at the time. The biologic's Phase 1 data showed that it could be dosed as infrequently as every three to six months. This would be a significant improvement over Sanofi's (SNY) multibillion-dollar Dupixent monthly dosing. I recommen ...